Vedolizumab biosimilar (Alvotech)

维得利珠单抗生物类似药 (Alvotech)

Report date: 2025/12/27 20:00:14

Base Information

Drug NameVedolizumab biosimilar (Alvotech)
Drug Alias NameAVT16AVT-16
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionMucosal addressin cell adhesion molecule-1 inhibitorsIntegrin alpha-4/beta-7 antagonists
TargetsMucosal addressin cell adhesion molecule-1Integrin alpha-4/beta-7
Therapy Area/IndicationsImmune System DiseasesColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUkraineSlovakia +[13] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAlvotech Swiss Ag
China Registration ClassN/A

Develop Information

Active CompaniesAlvotech Swiss AgAdvanz Pharma LtdAlvotech hf
Inactive CompaniesN/A
Active IndicationsImmune System Diseases
Inactive IndicationsColitis, Ulcerative

Other Information

ATC CodeL04AG05
Related LinksN/A